Segall Bryant & Hamill LLC Trims Stock Position in The Cooper Companies, Inc. (NASDAQ:COO)

Segall Bryant & Hamill LLC decreased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 6.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 99,820 shares of the medical device company’s stock after selling 6,601 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.05% of Cooper Companies worth $9,176,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp boosted its stake in Cooper Companies by 1.2% during the 3rd quarter. State Street Corp now owns 8,590,689 shares of the medical device company’s stock worth $947,897,000 after purchasing an additional 104,521 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Cooper Companies by 13.2% in the third quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after buying an additional 573,908 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Cooper Companies by 1.0% during the third quarter. Geode Capital Management LLC now owns 4,796,556 shares of the medical device company’s stock worth $527,476,000 after buying an additional 48,559 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Cooper Companies by 14.6% during the fourth quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock worth $415,985,000 after buying an additional 574,899 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Cooper Companies by 11.9% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,818,610 shares of the medical device company’s stock valued at $200,665,000 after acquiring an additional 194,118 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on COO shares. Piper Sandler reiterated an “overweight” rating and issued a $115.00 target price (down from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Robert W. Baird dropped their price objective on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. lowered their target price on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a report on Friday, March 7th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Cooper Companies presently has an average rating of “Moderate Buy” and a consensus target price of $110.25.

Cooper Companies Stock Up 0.2 %

COO stock opened at $83.86 on Thursday. The Cooper Companies, Inc. has a 52 week low of $77.05 and a 52 week high of $112.38. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The company has a market cap of $16.77 billion, a P/E ratio of 43.01, a P/E/G ratio of 2.25 and a beta of 1.02. The company’s 50-day moving average price is $89.66 and its 200 day moving average price is $97.62.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. The business had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. On average, research analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.